A Clinical Approach to Early-Onset Inheritable Dementia

American Journal of Alzheimer's Disease & Other Dementias®

Volumn 27, Issue 3, 2012, Pages 154-161

  Rogers, Brian S ^a   Lippa, Carol F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; early onset dementia; frontotemporal dementia; Kufs disease; Niemann Pick disease type C

Indexed keywords

ALZHEIMER DISEASE; DISEASE PREDISPOSITION; FRONTOTEMPORAL DEMENTIA; GENETICS; HUMAN; NEURONAL CEROID LIPOFUSCINOSIS; NIEMANN PICK DISEASE; PATHOPHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; DISEASE SUSCEPTIBILITY; FRONTOTEMPORAL DEMENTIA; HUMANS; NEURONAL CEROID-LIPOFUSCINOSES; NIEMANN-PICK DISEASE, TYPE C;

EID: 84865422864     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512444000     Document Type: Review

References (68)

1. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
2. The authors received no financial support for the research, authorship, and/or publication of this article.
3. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2011; 7(2):1-63.
4. Schmidt C Wolff M Weitz M Bartlau T Korth C Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011; 68 (9): 1124-1130.
5. Hebert LE Scherr PA Bienias JL Bennett DA Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60(8):1119-1122.
6. Harvey RJ Skelton-Robinson M Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003; 74(9):1206-1209.
7. Renvoize E Hanson M Dale M. Prevalence and causes of young onset dementia in an English health district. Int J Geriatr Psychiatry. 2011; 26(1):106-107.
8. Goate A Chartier-Harlin MC Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer-s disease. Nature. 1991; 349(6311):704-706.
9. Sherrington R Rogaev EI Liang Y. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer-s disease. Nature. 1995; 375(6534):754-760.
10. Levy-Lahad E Wasco W Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer-s disease locus. Science. 1995; 269(5226):973-977.
11. Rogaev EI Sherrington R Rogaeva EA, et al. Familial Alzheimer-s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer-s disease type 3 gene. Nature. 1995; 376(6543)775-778.
12. Schmechel DE Saunders AM Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90(20):9649-9653.
13. Strittmatter WJ Saunders AM Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993; 90(5):1977-1981.
14. Wingo TS Lah JJ Levey AI Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol. 2012; 69(1):59-64.
15. Karran E Mercken M De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10(9):698-712.
16. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997; 275(5300):630-631.
17. Braak H Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995; 16(3):271-278.
18. Licht EA McMurtray AM Saul RE Mendez MF. Cognitive differences between early- and late-onset Alzheimer-s disease. Am J Alzheimers Dis Other Demen. 2007; 22(3):218-222.
19. Balasa M Gelpi E Antonell A, et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology. 2011; 76(20):1720-1725.
20. Lippa CF Swearer JM Kane KJ, et al. Familial Alzheimer-s disease: site of mutation influences clinical phenotype. Ann Neurol. 2000; 48(3):376-379.
21. Birks J. Cholinesterase inhibitors for Alzheimer-s disease. Cochrane Database Syst Rev. 2006;(1): CD005593.
22. Cacabelos R Takeda M Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer-s disease. Int J Geriatr Psychiatry. 1999; 14(1):3-47.
23. McShane R Areosa Sastre A Minakaran N. Memantine for dementia. Coch Database Syst Rev 2006;(2):CD003154.
24. Brunden KR Trojanowski JQ Lee VM. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov. 2009; 8(10):783-793.
25. Gotz J Ittner A Ittner LM. Tau-targeted treatment strategies in Alzheimer-s disease. Br J Pharmacol. 2012; 165(5):1246-1259.
26. Frisardi V Solfrizzi V Imbimbo PB, et al. Towards disease-modifying treatment of Alzheimer-s disease: drugs targeting beta-amyloid. Curr Alzheimer Res. 2010; 7(1):40-55.
27. Rabinovici GD Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010; 24(5):375-98.
28. Rosso SM Donker Kaat L Baks T, et al. Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain. 2003; 126(9):2016-22.
29. Mercy L Hodges JR Dawson K, et al. Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology. 2008; 71(19):1496-1499.
30. Knopman DS Petersen RC Edland SD, et al. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004; 62(3):506-508.
31. Goldman JS Farmer JM Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005; 65(11):1817-1819.
32. Arvanitakis Z. Update on frontotemporal dementia. Neurologist. 2010; 16(1):16-22.
33. Baker M MacKenzie IR Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006; 442(7105):916-919.
34. Cruts M Gijselinck I can der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006; 442(7105):920-924.
35. Zhang YJ Xu YF Dickey CA, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007; 27(39):10530-10534.
36. Neary D Snowden JS Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998; 51(6):1546-1554.
37. Hodges JR. Frontotemporal dementia (Pick-s disease): clinical features and assessment. Neurology. 2001; 56(11 suppl 4): S6-S10.
38. Edwards-Lee T Miller BL Benson DF, et al. The temporal variant of frontotemporal dementia. Brain. 1997; 120(6):1027-1040.
39. Seeley WW Bauer AM Miller BL, et al. The natural history of temporal variant frontotemporal dementia. Neurology. 2005; 64(8):1384-1390.
40. Gorno-Tempini ML Dronkers NF Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004; 55(3):335-346.
41. Swartz JR Miller BL Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997; 58(5):212-216.
42. Ikeda M Shigenobu K Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004; 17(3):117-121.
43. Moretti R Torre P Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003; 49(1):13-19.
44. Moretti R Torre P Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer-s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003; 18(4):205-214.
45. Curtis RC Resch DS. Case of pick-s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000; 20(3):384-385.
46. Fellgiebel A Muller MJ Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007; 8(2):123-126.
47. Moretti R Torre P Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004; 21(14):931-937.
48. Kertesz A Morlog D Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008; 25(2):178-185.
49. Mendez MF Shapira JS McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007; 15(1):84-87.
50. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007; 21(2):164-166.
51. Pierret C Morrison JA Kirk MD. Treatment of lysosomal storage disorders: focus on the neuronal ceroid-lipofuscinoses. Acta Neurobiol Exp (Wars). 2008; 68(3):429-442.
52. Berkovic SF Carpenter S Andermann F Andermann E Wolfe LS. Kufs- disease: a critical reappraisal. Brain. 1988; 111(1):27-62.
53. Noskova L Stranecky V Hartmannova H, et al. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet. 2011; 89(2):241-252.
54. Benitez BA Alvarado D Cai Y, et al. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS One. 2011; 6(11):e26741.
55. Nardocci N Verga ML Binelli S Zorzi G Angelini L Bugiani O. Neuronal ceroid-lipofuscinosis: a clinical and morphological study of 19 patients. Am J Med Genet. 1995; 57(2):137-141.
56. Wisnieweski KE Gordon-Majszak W Maslinski S Heaney-Kieras J. Altered protein patterns in brains of children with neuronal ceroid lipofuscinosis. Am J Med Genet. 1992; 42(4):568-574.
57. Callagy C O-Neill G Murphy SF Farrell MA. Adult neuronal ceroid lipofuscinosis (Kufs- disease) in two siblings of an Irish family. Clin Neuropathol. 2000; 19(3):109-118.
58. Ivan CS Saint-Hilaire MH Christensen TG Milunsky JM. Adult-onset neuronal ceroid lipofuscinosis type B in an African-American. Mov Disord. 2005; 20(6):752-754.
59. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010; 5: 16.
60. Steinberg SJ Ward CP Fensom AH. Complementation studies in Niemann-Pick disease type C indicate the existence of a second group. J Med Genet. 1994; 31(4):317-320.
61. Vanier MT Duthel S Rodriguez-Lafrasse C Pentchev P Carstea ED. Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am J Hum Genet 1996; 58(1):118-125.
62. Carstea ED Morris JA Coleman KG, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science. 1997; 277(5323):228-231.
63. Naureckiene S Sleat DE Lackland H, et al. Identification of HE1 as the second gene of Niemann- Pick C disease. Science. 2000; 290(5500):2298-2301.
64. Higgins ME Davies JP Chen FW, Ioannou YA. Mol Genet Metab. 1999; 68(1):1-13.
65. Patterson MC Vecchio D Prady H Abel L Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007; 6(9):765-772.
66. Wraith JE Vecchio D Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab. 2010; 99(4):351-357.
67. Wagner GS McClintock SM Rosenquist PB McCall WV Kahn DA. Major depressive disorder with psychotic features may lead to misdiagnosis of dementia: a case report and review of the literature. J Psychiatr Pract. 2011; 17(6):432-438.
68. Ballard C Gauthier S Corbett A Brayne C Aarsland D Jones E. Alzheimer's disease. Lancet. 2011; 377(9770):1019-1031.